Investors & Media Press Releases
Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones
01.03.2019
- Axovant’s CEO, Pavan Cheruvu, M.D., will be presenting at the
J.P. Morgan Healthcare Conference at8:00 a.m. PST onThursday, January 10 th, 2019 - Initial clinical data expected in first half of 2019 from the AXO-AAV-GM2 and AXO-Lenti-PD gene therapy programs
- Axovant assembles
Scientific Advisory Board to provide strategic guidance across its gene therapy portfolio
Over the course of the last year, Axovant has strategically built integrated capabilities for the development, manufacturing and commercialization of novel gene therapies, including:
- In-licensing and developing a pipeline of innovative, clinical-stage product candidates in partnership with well-recognized gene therapy organizations
- Assembling a team with decades of gene therapy expertise spanning regulatory affairs, clinical development, vector optimization and delivery, manufacturing and commercialization
- Assembling a world-class
Scientific Advisory Board to provide strategic guidance across its gene therapy development programs - Raised over
$55 million in 2018, including a$30 million equity financing inDecember 2018 led byDeerfield Management Company , Sphera Funds Management and Roivant Sciences that will enable the company to reach certain key clinical milestones in 2019
“Building on our progress in 2018, Axovant is harnessing innovations in gene therapy to address the unmet needs of patients with debilitating neurological diseases,” said Pavan Cheruvu, M.D., CEO of Axovant. “We anticipate that 2019 will highlight Axovant’s steadfast commitment to becoming a leader in the development of novel gene therapies. We are eager to accelerate our pipeline of product candidates through important clinical milestones and data readouts in 2019.”
Upcoming Milestones Anticipated in 2019
Axovant expects to advance its pipeline of innovative gene therapy programs through multiple milestones in 2019:
- AXO-AAV-GM1: First patient expected to be dosed in the first half of 2019; initial data expected in second half of 2019
- AXO-AAV-GM2: Initial data expected in the first quarter of 2019
- AXO-Lenti-PD: Initial data expected in
March 2019 - AXO-AAV-OPMD: Initiation of clinical program expected in the second half of 2019
Formation of
In
Michael Hayden , M.B. Ch.B., Ph.D., F.R.S.C. - chair of theScientific Advisory Board and senior scientific advisor to Axovant, former chief scientific officer and president of global R&D at TevaBeverly Davidson , Ph.D. - chief scientific strategy officer, Arthur V. Meigs Chair in Pediatrics and director of theRaymond G. Perelman Center for Cellular and Molecular Therapeutics at Children’s Hospital ofPhiladelphia (CHOP); professor, department of pathology and laboratory medicine atUniversity of Pennsylvania ; scientific co-founder ofSpark Therapeutics R. Jude Samulski , Ph.D. - professor, department of pharmacology atUniversity of North Carolina School of Medicine and director of theUniversity of North Carolina Gene Therapy Center ; scientific founder of Bamboo Therapeutics- Nicole Déglon, Ph.D. - research director and deputy director of the
Molecular Imaging Research Center (MIRCen) and associate professor in Clinical Neurosciences at theLausanne University Hospital (CHUV) Jeffrey Kordower , Ph.D. - the Alla V. and Solomon Jesmer Professor of Neurological Sciences, director of theResearch Center for Brain Repair and section head of neuroscience atRush University Medical Center Luigi Naldini , M.D., Ph.D. - professor of cell and tissue biology and of gene and cell therapy at theSan Raffaele University School of Medicine and scientific director of theSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET)Guy Rouleau , Ph.D. - director of theMontreal Neurological Institute and Hospital and chair of theDepartment of Neurology and Neurosurgery atMcGill University
“It was a pleasure to bring together these pre-eminent leaders in gene therapies and neurodegenerative disorders to discuss the latest developments in their fields,” said Dr. Hayden, chair of the
Webcast Information for
A live audio webcast of the presentation can be accessed on the “Events and Presentations” page of the “Investors” section of the Company’s website at http://investors.axovant.com. A replay of the webcast will be available following the live event.
About Axovant
In
AXO-Lenti-PD, licensed from
AXO-AAV-OPMD, licensed from
For more information, visit www.axovant.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “expect,” “plan,” “anticipate,” “believe,” “intend,” “future,” or “continue” and other similar expressions are intended to identify forward-looking statements. For example, all statements Axovant makes regarding the potential efficacy of its product candidates; initiation, timing, progress, and reporting of results of its preclinical programs, clinical trials, and research and development programs; its ability to advance its product candidates into and successfully initiate, enroll, and complete clinical trials; and the timing or likelihood of its regulatory filings and approvals, are forward-looking. All forward-looking statements are based on estimates and assumptions by Axovant’s management that, although Axovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Axovant expected. Such risks and uncertainties include, among others, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the expectations for regulatory submissions and approvals; the continued development of its product candidates and platforms; Axovant’s scientific approach and general development progress; and the availability or commercial potential of Axovant’s product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Axovant’s most recent Quarterly Report on Form 10-Q for the quarterly period ended
Contacts:
Media
Axovant
(646) 802-3585
media@axovant.com
Sam Brown Inc.
(312) 961-2502
mikebeyer@sambrown.com
Investors
Axovant
(631) 892-7014
investors@axovant.com
Source: Axovant Sciences Ltd.